New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy
More than 90% of patients had a complete response to novel treatment combination
After two years, 97% of patients remained cancer free
Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of therapies – brentuximab vedotin and nivolumab combined with chemotherapy drugs doxorubicin and dacarbazine...
Dual-antigen targeting of large B-cell lymphoma shows promise in reducing relapse
Large B-cell lymphoma (LBCL) is an aggressive blood cancer with few treatment options
CAR T cell therapy targeting...